INFO	DRM.	ATIO	ON DIS	CLOS	JRE CIT	TATION	AT	ATTY. DOCKET NO. PC10434B SERIAL NO. 09/845,992									
(Use severe) speets if he sessary)								APPLICANT Howard Ralph Howard									
				720	B 2		FILING DATE April 30, 2001					GROUP 1626					
	· · · · · · · · · · · · · · · · · · ·		1 1	SB.	₹]	Į		PATENT	DOCU	MENTS							
EXAMINE INITIAL				_	THE DOC	UMENT NUMBE	R			DATE	NAME	С	LASS	SUBCLASS	1 1	ODATE IF OPRIATE	
	l u	s	1	1	6	1	5	2	9	11/23/15	R. R. Ringe	er				-	
									<del></del>		<u> </u>						
							· · · -								<del>                                     </del>		
								:			F	7	D			<del></del>	
		-	<del></del>					<u> </u>		_		CENTER 1800	T	<u> </u>			
												CE P		ή_			
												可言	_	3	:		
	:								•			60	2003	G			
						,			-			de 200	1-1	,			
												3		<u></u>			
											-			<u> </u>			
													<u></u>				
FOREIGN PATENT DOCUMENTS																	
DOCUMENT NUMBER										DATE	COUNTRY	Cı	CLASS S	SUBCLASS	TRANSI	LATION	
	<del></del>			<u> </u>		<del> </del>		<del>'' '' '</del>	<del></del>						YES	NO	
	E	Р	T	8	1	6	2	3	4	5/25/92							
	E		0	8	0	7	6	2	1	5/12/97	<del></del>						
	S	J	1	2	<u> </u>	8	7	0	5	6/26/84	<del></del> -		-				
	S	ار	2	1	3	8	8	7	7	2/14/97							
														i			
				OTHER	R DOCU	MENTS (	Inclu	iding Aut	hor, Titl	e, Date, P	ertinent Page	s, Etc.)					
			Databa	ase CSCI	nem, Cher	nical Source	es Inte	ernational, I	nc. Retrie	ved from ST	N Database Acc	ession No	0. 112	50 XP002	13547	7	
			Database CSChem, Chemical Sources International, Inc. Retrieved from STN Database Accession No. 11250, XP002135477, 2-Aminomethyl-3-Chlorodipfenylether.														
											·						
		,									_				······································		
EXAMIN	IER								DATE CO	ONSIDERED	)						
EXAMINER with next co	R: Initia ommuni	if refe	rence cons to applican	idered, whet	her or not cit	ation is in confo	rmance	with MPEP 60	9; Draw line	through citation if	not in conformance a	and not consi	idered. I	nclude copy of	this form	n	

Conforms with FORM PTO-FB-A820

Attorney Docket No.PC10434B2

Tares/Postal Service as first-class mail in an envelope addressed pil 2003.

Troon mailing)

Joran

## O LE JC87 JEST & THE STREET

I hereby certify that this correspondence is being deposited with the United States/Postal Service as first-class mail in an envelope address: Commissioner of Patents, Washington, D.C. 20231 on this 2nd day of April 2003.

(Signature of person mailing)

A. David Joran

(Typed or printed name of person)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Harry Ralph Howard:

APPLICATION NO.: 09/845,992 : Examiner: Saeed, K. A.

FILING DATE: April 30, 2001 : Group Art Unit: 1626

TITLE: MONOAMINE REUPTAKE :

INHIBITORS FOR TREATMENT OF

CNS DISORDERS

Commissioner for Patents Washington, D.C. 20231

Sir:

## INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97 (c) (1) AND CERTIFICATE UNDER 37 CFR §1.97 (e) (1)

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

Since the references cited were cited in a communication from a foreign patent office in connection with a counterpart application not more than three months prior to this statement, no fee is believed to be due. However, if a fee is deemed to be due, the Commissioner is hereby authorized to charge all appropriate fees to cover this submission to Pfizer Deposit Account No. 16-1445.

A prompt and favorable response is earnestly solicited.

## CERTIFICATE UNDER 37 CFR § 1.97 (e) (1)

Applicants' undersigned attorney avers that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of this Information Disclosure Statement.

Date:

(XX)

A. David Joran

Attorney for Applicant(s)

Respectfully submitted,

Reg. No. 37,858

Pfizer Inc Patent Department, 5th Floor 150 East 42nd Street New York, NY 10017-5755 (212)733 -3381